Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 12/20 | 0.69 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.68 |
| ▸ | AKR1B1 | P15121 | 1/20 | 0.68 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.67 |
| ▸ | LIPG | Q9Y5X9 | 1/20 | 0.61 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.60 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.60 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.60 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.60 |
| ▸ | PLA2G10 | O15496 | 1/20 | 0.57 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.57 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.57 |
| ▸ | PTPRB | P23467 | 1/20 | 0.57 |
| ▸ | CDC25A | P30304 | 1/20 | 0.57 |
| ▸ | CDC25B | P30305 | 1/20 | 0.57 |
| ▸ | PTEN | P60484 | 1/20 | 0.57 |
| ▸ | PTPMT1 | Q8WUK0 | 1/20 | 0.57 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29381971 | 1.00 | FFAR1 (0.69) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL9194505 | 0.89 | HDAC1 (0.69) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL21854583 | 0.89 | MMP12 (0.56) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL26133929 | 0.88 | FFAR1 (0.59) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL30671117 | 0.88 | FFAR1 (0.71) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| Biphenyl SCHEMBL31099230 | 0.88 | FFAR1 (0.88) | FFAR1FFAR4AKR1B1KEAP1HDAC3 | |
| SCHEMBL7763090 | 0.87 | MAPT (0.68) | FFAR1FFAR4AKR1B1PTGER1PTGER4 | |
| SCHEMBL23512360 | 0.87 | FFAR1 (0.62) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| SCHEMBL13525204 | 0.86 | FFAR1 (0.71) | FFAR1FFAR4AKR1B1KEAP1LIPG | |
| Biphenyl SCHEMBL31099239 | 0.86 | FFAR1 (0.84) | FFAR1FFAR4AKR1B1KEAP1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101094827-B | Benzene compound having two or more substituents | DAIICHI SANKYO CO LTD | 2012-06-13 | — | — | CN | claimed |
| CN-101094827-A | Benzene compound having two or more substituents | SANKYO CO (JP) | 2007-12-26 | — | — | CN | claimed |
| CN-1103332-C | Biphenyl-5-alkanoic acid derivs. and use thereof | ASAHI CHEMICAL IND (JP) | 2003-03-19 | — | — | CN | claimed |
| CN-1276778-A | Biphenyl-5-alkanoic acid derivs. and use thereof | ASAHI CHEMICAL IND (JP) | 2000-12-13 | — | — | CN | claimed |
| EP-0889877-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1999-01-13 | — | — | EP | claimed |
| EP-0850221-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1998-07-01 | — | — | EP | claimed |
| WO-1997036862-A1 | META-SUBSTITUTED PHENYLENE DERIVATIVES AND THEIR USE AS ALPHAvBETA3 INTEGRIN ANTAGONISTS OR INHIBITORS | G.D. SEARLE & CO. (US) | 1997-10-09 | — | — | WO | claimed |
| WO-1997008145-A1 | META-GUANIDINE, UREA, THIOUREA OR AZACYCLIC AMINO BENZOIC ACID DERIVATIVES AS INTEGRIN ANTAGONISTS | G.D. SEARLE & CO. (US) | 1997-03-06 | — | — | WO | claimed |
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | OPHIREX, INC. (US) | 2025-08-12 | — | — | US | disclosed |
| US-20250120950-A1 | USE OF SPLA2 INHIBITORS TO TREAT HYMENOPTERA ENVENOMATION, HEMOLYSIS, AND KIDNEY DISEASE, AND TO PROTECT BLOOD FROM OSMOTIC FRAGILITY | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | OPHIREX, INC. (US) | 2025-04-17 | — | — | US | disclosed |
| EP-3448378-B1 | PLA2 AND HMG-COA INHIBITORS FOR TREATMENT OF PATHOLOGICAL CONDITIONS CAUSING HEMOLYSIS, CEREBRAL EDEMA, AND ACUTE KIDNEY INJURY | OPHIREX INC (US) | 2024-04-17 | — | — | EP | disclosed |
| CN-116585306-A | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-08-15 | — | — | CN | disclosed |
| CN-109562098-B | PLA2 inhibitors for immediate treatment of hymenoptera toxicity and other conditions due to histamine release | 奥菲瑞克斯股份有限公司 | 2023-04-21 | — | — | CN | disclosed |
| CN-1942436-A | Lysine-based compounds | PROCYON BIOPHARMA INC (CA) | 2007-04-04 | — | — | CN | disclosed |
| CN-1653032-A | Substituted phenylalkanoic acid derivatives and use thereof | ASAHI CHEMICAL IND (JP) | 2005-08-10 | — | — | CN | disclosed |
| CN-1103332-C | Biphenyl-5-alkanoic acid derivs. and use thereof | ASAHI CHEMICAL IND (JP) | 2003-03-19 | — | — | CN | disclosed |
| CN-1367778-A | Novel carboxylic acid derivatives having a 5, 6-substituted pyrimidine ring, method for the production thereof and use thereof as endothelin receptor antagonists | BASF AG (DE) | 2002-09-04 | — | — | CN | disclosed |
| CN-1276778-A | Biphenyl-5-alkanoic acid derivs. and use thereof | ASAHI CHEMICAL IND (JP) | 2000-12-13 | — | — | CN | disclosed |
| EP-0212859-A2 | Fungicides | IMPERIAL CHEMICAL INDUSTRIES PLC (GB) | 1987-03-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12383531-B2 | PLA2 inhibitors for treatment of pathological conditions caused by hymenoptera envenomation, such as hemolysis, cerebral edema, and acute kidney injury | PLA2G4A, PLA2G12A, PLA2G6 | FFAR1 1058/4885FFAR4 682/4885AKR1B1 2375/4885 |
| US-20250120950-A1 | USE OF SPLA2 INHIBITORS TO TREAT HYMENOPTERA ENVENOMATION, HEMOLYSIS, AND KIDNEY DISEASE, AND TO PROTECT BLOOD FROM OSMOTIC FRAGILITY | PLA2G12A, PLA2G2D, PLA2G2E | FFAR1 3975/4885FFAR4 4013/4885AKR1B1 4224/4885 |
| US-20250120949-A1 | USE OF SPLA2 INHIBITORS TO TREAT ENVENOMATION BY SNAKES AND WASPS | PLA2G12A, PLA2G2D, PLAAT2 | FFAR1 2736/4885FFAR4 2788/4885AKR1B1 4624/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.